These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 24030279)
1. Gene patents and capital investment. The consequences of the revocation of Myriad's patents on the BRCA genes on venture capital investment in the life sciences. Wolinsky H EMBO Rep; 2013 Oct; 14(10):871-3. PubMed ID: 24030279 [No Abstract] [Full Text] [Related]
2. The people vs patents. New Sci; 2002 Jul; 175(2351):3. PubMed ID: 12625337 [No Abstract] [Full Text] [Related]
3. Personalized Medicine in the Information Age: Myriad's De Facto Monopoly on Breast Cancer Research. Oliver AM SMU Law Rev; 2015; 68(2):537-66. PubMed ID: 30028113 [No Abstract] [Full Text] [Related]
4. Your money or your life. Westphal SP New Sci; 2002 Jul; 175(2351):28-33. PubMed ID: 12625339 [No Abstract] [Full Text] [Related]
5. Entrepreneurship in the medical academy: possibilities and challenges in commercialization of research discoveries. Loscalzo J Circulation; 2007 Mar; 115(12):1504-7. PubMed ID: 17389277 [No Abstract] [Full Text] [Related]
6. European groups oppose Myriad's latest patent on BRCA1. Benowitz S J Natl Cancer Inst; 2003 Jan; 95(1):8-9. PubMed ID: 12509391 [No Abstract] [Full Text] [Related]
7. Napster case spills into biotech sector. Bouchie A Nat Biotechnol; 2004 Sep; 22(9):1185-6. PubMed ID: 15384189 [No Abstract] [Full Text] [Related]
8. Life support for life science innovation? Nat Biotechnol; 2007 Feb; 25(2):144. PubMed ID: 17287731 [TBL] [Abstract][Full Text] [Related]
9. IBM opens the IP vaults. Mack GS Nat Biotechnol; 2006 Apr; 24(4):385-6. PubMed ID: 16710902 [No Abstract] [Full Text] [Related]
10. Battle brewing over the BRCA1/2 gene patents. Agovic A Rev Derecho Genoma Hum; 2010; (33):171-94. PubMed ID: 21510137 [TBL] [Abstract][Full Text] [Related]
11. Venture capital for the pharmacologist. Miller LG Mol Interv; 2001 Dec; 1(5):242-4. PubMed ID: 14993362 [No Abstract] [Full Text] [Related]
12. The rise of European venture capital for biotechnology. Howell M; Trull M; Dibner MD Nat Biotechnol; 2003 Nov; 21(11):1287-91. PubMed ID: 14595356 [No Abstract] [Full Text] [Related]
13. US venture capital for biotechnology. Dibner MD; Trull M; Howell M Nat Biotechnol; 2003 Jun; 21(6):613-7. PubMed ID: 12776144 [No Abstract] [Full Text] [Related]
14. Bottom-up innovation. Venture capital change may foster entrepreneurial growth. Limbacher PB Mod Healthc; 1998 Aug; 28(32):64. PubMed ID: 10183072 [No Abstract] [Full Text] [Related]
15. Start-ups: A sense of enterprise. Savage N Nature; 2016 May; 533(7601):S10-2. PubMed ID: 27144602 [No Abstract] [Full Text] [Related]
16. In defense of life sciences venture investing. Booth BL; Salehizadeh B Nat Biotechnol; 2011 Jul; 29(7):579-83. PubMed ID: 21747380 [No Abstract] [Full Text] [Related]
17. Direct to confusion: lessons learned from marketing BRCA testing. Matloff E; Caplan A Am J Bioeth; 2008 Jun; 8(6):5-8. PubMed ID: 18726769 [TBL] [Abstract][Full Text] [Related]
18. History of a gene patent: tracing the development and application of commercial BRCA testing. Williams-Jones B Health Law J; 2002; 10():123-46. PubMed ID: 14748275 [No Abstract] [Full Text] [Related]
19. The importance of angels in starting a US biotech venture. Sohl J Nat Biotechnol; 2005 Feb; 23(2):263-4. PubMed ID: 15724275 [No Abstract] [Full Text] [Related]